What clinical trials are needed for treatment of leiomyosarcoma?

Leiomyosarcoma is one of the most common subtypes of soft tissue sarcomas accounting for approximately 20% of sarcomas. As leiomyosarcoma patients frequently develop metastatic disease, effective systemic therapies are needed to improve clinical outcomes. The overall activity of the currently availa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kasper, Bernd (VerfasserIn) , D’Ambrosio, Lorenzo (VerfasserIn) , Davis, Elizabeth J. (VerfasserIn) , Ingham, Matthew (VerfasserIn) , Broto, Javier Martin (VerfasserIn) , Trent, Jonathan C. (VerfasserIn) , van Houdt, Winan J. (VerfasserIn) , Van Tine, Brian A. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11 March 2022
In: Current treatment options in oncology
Year: 2022, Jahrgang: 23, Heft: 3, Pages: 439-449
ISSN:1534-6277
DOI:10.1007/s11864-021-00928-y
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s11864-021-00928-y
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s11864-021-00928-y
Volltext
Verfasserangaben:Bernd Kasper, Lorenzo D’Ambrosio, Elizabeth J. Davis, Matthew Ingham, Javier Martin Broto, Jonathan C. Trent, Winan J. van Houdt, Brian A. Van Tine
Beschreibung
Zusammenfassung:Leiomyosarcoma is one of the most common subtypes of soft tissue sarcomas accounting for approximately 20% of sarcomas. As leiomyosarcoma patients frequently develop metastatic disease, effective systemic therapies are needed to improve clinical outcomes. The overall activity of the currently available conventional systemic therapies and the prognosis of patients with advanced and/or metastatic disease are poor. As such, the treatment of this patient population remains challenging. As a result, there is a clear unmet medical need, and designing and performing meaningful clinical studies are of utmost importance to improve the prognosis of this patient group. Therefore, the aim of this review is to briefly summarize state-of-the-art treatments for leiomyosarcoma patients and to describe trial characteristics needed for informative clinical studies.
Beschreibung:Am Ende des Titels ist ein Fragezeichen geschrieben
Gesehen am 23.04.2024
Beschreibung:Online Resource
ISSN:1534-6277
DOI:10.1007/s11864-021-00928-y